Marc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for the company’s Genzyme unit. A pharmaceutical physician with experience in R&D, global medical affairs ...
Boston, USA-based biotech Sionna Therapeutics has recently raised $191 million through its initial public offering (IPO), marking a step forward in its efforts to develop treatments for cystic ...
Under the new structure, due to come into effect next January, Sanofi's cancer and immunology pipeline with now sit alongside subsidiary Genzyme's rare disease and multiple sclerosis (MS ...
OMass Therapeutics appoints Birgitte Volck as Non-Executive DirectorOxford, United Kingdom – 26 February 2025 – OMass Therapeutics (‘OMass’ or ...
MS: has received consulting and speaker honoraria as well as travel reimbursements from Bayer, Biogen, Celgene, Roche, Sanofi Genzyme and Teva and research funding from the Hertha-Nathorff-Program and ...
Other prior executive leadership roles include developing and launching innovative therapies for specialty care and rare disease indications at Sobi, Amgen, and Genzyme. Furthermore, she has ...
Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, ...
Researchers found increased odds for clinical remission on dupilumab with high blood eosinophil and fractional exhaled nitric ...
The FDA has accepted the supplemental new drug application for Zoryve cream 0.05% to treat mild to moderate atopic dermatitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback